CIK 0001287098 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MAXCYTE, INC.
Sign in to watch- Ticker
- MXCT
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522210438
- Phone
- 301-517-5556
- Business address
- 9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, MD, 20850
- Former names
- MAXCYTE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 42 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-03 | Ross Thomas M. EVP, Global Sales & Marketing | Option exercise 10b5-1 | +100 | $2.14 | $214 | 100 |
| 2023-04-03 | Ross Thomas M. EVP, Global Sales & Marketing | Sale 10b5-1 | −100 | $5.01 | $501 | 0 |
| 2023-04-03 | Ross Thomas M. EVP, Global Sales & Marketing | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −100 | 69,428 | ||
| 2023-04-03 | Doerfler Douglas President and CEO | Option exercise 10b5-1 | +100 | $0.04 | $4 | 333,297 |
| 2023-04-03 | Doerfler Douglas President and CEO | Sale 10b5-1 | −100 | $5.01 | $501 | 333,197 |
| 2023-04-03 | Doerfler Douglas President and CEO | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −100 | 382,373 | ||
| 2023-03-31 | Ross Thomas M. EVP, Global Sales & Marketing | Option exercise 10b5-1 | +2,607 | $2.14 | $6K | 2,607 |
| 2023-03-31 | Ross Thomas M. EVP, Global Sales & Marketing | Sale 10b5-1 | −2,607 | $5.00 | $13K | 0 |
| 2023-03-31 | Ross Thomas M. EVP, Global Sales & Marketing | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,607 | 69,528 | ||
| 2023-03-31 | Doerfler Douglas President and CEO | Option exercise 10b5-1 | +2,607 | $0.04 | $104 | 335,804 |
| 2023-03-31 | Doerfler Douglas President and CEO | Sale 10b5-1 | −2,607 | $5.00 | $13K | 333,197 |
| 2023-03-31 | Doerfler Douglas President and CEO | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −2,607 | 382,473 | ||
| 2023-03-29 | DOUGLAS RICHARD Director | Purchase | +80,000 | $4.32 | $345K | 100,000 |
| 2023-03-27 | Swirsky Douglas J Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2023-03-20 | Holtz Ron Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2023-03-20 | Hemrajani Rekha Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-03-20 | Al-Wakeel Yasir B. Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-03-20 | Masoud Maher EVP and General Counsel | Grant or award · Employee Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2023-03-20 | Ross Thomas M. EVP, Global Sales & Marketing | Grant or award · Employee Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2023-03-20 | Doerfler Douglas President and CEO | Grant or award · Employee Stock Option (right to buy) | +400,000 | 400,000 |
Page 14 of 15 · 282 trades